• Setting up a new medicinal solid dosage forms manufacturing facility
Enterprise description
Full name of the company
Joint Stock Company “Borisovskiy zavod medicinskikh preparatov”
Ownership
Private
Year of establishment
1965
Primary activity
Manufacture of pharmaceutical products
Superior body
The Pharmaceutical Holdings Company "Belpharmprom"
General reference and analytical information about the company
Today “BZMP” JSC is a leading manufacturer and exporter of broad-spectrum medicinal products in the Republic of Belarus and is a modern, dynamically developing pharmaceutical company, boasting cutting edge technology and advanced production culture. The impressive manufacturing range and scope of the company: more than 5 billion tablets, 350 million ampoules, 200 million capsules, 50 million flasks of antibiotics in the form of sterile powders, 17 million tubes of ointments and gels, 15 million bottles of tinctures and alcohol on an annual basis help improve people's health all over the world. The company’s industrial output in terms of the 2021-prices amounted 372,3 million rubles (equal to 146,7 million USD). Manufactured by “BZMP” JSC medicines are regularly supplied not only to the neighboring Russian Federation, but also to Azerbaijan, Armenia, Afghanistan, Georgia, Iraq, etc.
Cost effectiveness and solvency indicators of the company (before project implementation)
Project description
Infrastructure necessary for project implementation
Send Interested Export to Pdf Export to Word
  • Setting up a new medicinal solid dosage forms manufacturing facility
  • Type of investment project Предлагаемые для реализации инвестиционные проекты
  • Sector Pharmacy (CF)
  • Total volume of investments, thousand $ 49 707
  • Expected input of an investor, thousand $ 20 000
  • Project period 2021-2029
  • Investor participation form создание нового производства (предприятия)
  • Project description A new seven-storey manufacturing workshop for GMP-compliant production of finished solid dosage forms with an annual production capacity of 1.336 million tablets is planned for construction in accordance with the design and estimate documentation. The new production facility will help master the production of new highly marketable medicinal products and further increase the production output, leading to supply of a broader range of import-substituting drugs for the domestic and foreign markets.

The nomenclature of the product to be produced with indication of the CN FEA code

Nomenclature of the intended for manufacture products with their customs tariff numbers (HS codes) specified (3004900009-Medicinal products)

    The above medicinal products (MP) belong to the most marketable pharmaceutical groups:

      - MP for treatment of cardiovascular diseases (Bisoprolol, Amiodarone, Simvastatin, Aminalone, Detraven, Detraven 1000);

        - MP for treatment of type 2 diabetes (Metformin, Metformin Long);

          - Non-steroidal anti-inflammatory medicinal products, antispasmodics (Ibuprofen, Ibuprofen MAX, Spasmaton, Spasmaton Neo, Meloxicam);

            - MP for treatment of gastrointestinal disorders (Metoclopramide, Bisacodyl);

              - Vitamins (Ascorbic acid with glucose, Folic acid).

                  • Potential customer Potential customers and sales markets for products (services, technology): the manufactured products are designed to meet the needs of healthcare centers and patients for highly effective medicinal products which are distributed through the state owned pharmacy network of RUP "Farmatsia", private networks as well as healthcare and preventive treatment institutions. Sales markets: domestic market of the Republic of Belarus, Russian Federation, other CIS countries and non-CIS countries
                  • Key benefits of the project 1. Developed brand 2. Highly qualified staff 3. Raw materials & components supply network 4. Distribution network
                  • Level of project development Project preparation stage: the business plan (was approved by the General Director of JSC “BZMP” on 18.01.2022), design and estimate documentation has been prepared and the project has been examined and endorsed by the team of state experts. Currently, the implementation of the investment project "Creation of a new production of medicinal solid dosage forms" (1st stage) - engineering preparation of the construction site is underway. Carrying out of construction and installation works and putting the 1st stage into operation are scheduled for 2022.
                  • Full name of the company Joint Stock Company “Borisovskiy zavod medicinskikh preparatov”
                  • Form of ownership Private
                  • Year of establishment 1965
                  • Primary activity Manufacture of pharmaceutical products
                  • Superior body The Pharmaceutical Holdings Company "Belpharmprom"
                  • Region Minsk Region
                  • District Borisov District
                  • Address Republic of Belarus, Borisov, st. Chapaev, 64а
                  • GPS coordinates 54.19261,28.49242
                  • Avaliability of land plot for project implementation Avaliability of land for project realization
                  • Land area, ha 0.50
                  • Annual revenues once fully operational (without VAT, thousand $) 145 401
                  • Simple pay-back period, yrs 9.5
                  • Dymanic pay-back period, yrs 14
                  • NPV, thousand $ 2
                  • IRR, % 5
                  • Discount Rate, % 4.4
                  • Setting up a new medicinal solid dosage forms manufacturing facility
                  • General reference and analytical information about the company Today “BZMP” JSC is a leading manufacturer and exporter of broad-spectrum medicinal products in the Republic of Belarus and is a modern, dynamically developing pharmaceutical company, boasting cutting edge technology and advanced production culture. The impressive manufacturing range and scope of the company: more than 5 billion tablets, 350 million ampoules, 200 million capsules, 50 million flasks of antibiotics in the form of sterile powders, 17 million tubes of ointments and gels, 15 million bottles of tinctures and alcohol on an annual basis help improve people's health all over the world. The company’s industrial output in terms of the 2021-prices amounted 372,3 million rubles (equal to 146,7 million USD). Manufactured by “BZMP” JSC medicines are regularly supplied not only to the neighboring Russian Federation, but also to Azerbaijan, Armenia, Afghanistan, Georgia, Iraq, etc.
                  • Authorized capital size of the company, thousand $ 109 193
                  • Distribution of shares (by owners) Republican Unitary Mother Holding Company “Belfarmprom” - 99.989%; Legal entities - 0.0021%, Individuals - 0.0089%.
                  • Revenue, thousand $ 145 101
                  • Current liquidity ratio 4.75
                  • Working capital financed by equity to total assets ratio 0.79
                  • Number of employees as on the month of filling the form, people 2
                  • Average salary as on the month of filling the form, BYN 1 408
                  • Setting up a new medicinal solid dosage forms manufacturing facility
                  Investment projects and PPP
                  Investment ideas
                  Manufacturing sites and real estate
                  Concessions
                  Land Plots

                  STATISTICAL DATA FOR Borisov District